Sat Kartar Life Ltd
Sat Kartar Life Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management said on revenue, margins and capex.
The short version
Sat Kartar aims to reach INR 200+ crores revenue in 2026 and INR 300 crores by FY 2027. PAT margin expected to grow from 6% in the past to 9-10% in the current year, targeting 12-15% by FY '27 and aiming for 18-20% EBITDA margin in the near future.
From Sat Kartar Life Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Sat Kartar aims to reach INR 200+ crores revenue in 2026 and INR 300 crores by FY 2027.
- The company targets INR 500 crores revenue by FY 2028, focusing mainly on Ayurveda products.
- Hospital segment (300 beds) expected to be operational by Q4 FY '27 but not included in revenue projections so far.
- Manufacturing capacity built for capsule and powder products; aiming to self-manufacture about 50% of capsules by Q1 next year.
- Growth driven by increased repeat rates (now calculated across product range per customer, currently at 25%) and average ticket size rise (~5% increase to ~INR 3,300).
- AI-driven analytics and digital initiatives to boost customer acquisition and optimize sales.
- Capacity utilization of new manufacturing started at 10%, expected to ramp up gradually.
2 more points from Sat Kartar Life Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
Read what Sat Kartar Life Ltd said on margins in the Q2 FY26 call
Free account with your mobile number. We text a one-time code, no password.
Capital Expenditure Plans
- Sat Kartar has opened a manufacturing factory with minimal capex (less than INR 1 crore), focusing on producing up to 50% of capsule intake (about 25% of total intake) to maintain supply chain flexibility and serve as an R&D lab.
- Planning to start manufacturing 50% of capsules by Q1 FY 2026.
- Setting up a 300-bed Ayurveda hospital expected to be operational by Q4 FY 2027, starting with 30 beds in Q1 FY 2027 near NCR region.
- No immediate plan for equity raise; future funding for hospitals and growth expected through internal accruals.
- AI-driven initiatives are being launched to enhance data utilization and sales efficiency.
2 more points from Sat Kartar Life Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Sat Kartar Life Ltd said on fundraising & capital structure — free account, 30 seconds.
Continue your research
What Sat Kartar Life Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Bajaj Healthcare Ltd (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p
- Wanbury (Q2 FY26)
Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against
- Balaxi Pharmaceuticals Ltd (Q2 FY26)
Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee
- Emcure Pharmaceuticals Ltd (Q2 FY26)
Emcure Pharmaceuticals delivered a strong Q2 FY26 with 25% PAT growth, reporting highest quarterly profit of INR 251 crores. Key concall takeaways from Emcure…
Arthneeti Pro · Annual
Sat Kartar Life Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Sat Kartar Life Ltd Q2 FY26 results?
Sat Kartar aims to reach INR 200+ crores revenue in 2026 and INR 300 crores by FY 2027. PAT margin expected to grow from 6% in the past to 9-10% in the current year, targeting 12-15% by FY '27 and aiming for 18-20% EBITDA margin in the near future.
What is Sat Kartar Life Ltd share price analysis?
Sat Kartar Life Ltd currently shows a neutral. The stock trades at a P/E of 11.4 with a market cap of ₹196 Cr. Investors should review the full earnings analysis for detailed insights.
Is Sat Kartar Life Ltd planning capital expenditure?
Sat Kartar has opened a manufacturing factory with minimal capex (less than INR 1 crore), focusing on producing up to 50% of capsule intake (about 25% of total intake) to maintain supply chain flexibility and serve as an R&D lab.
Keep Sat Kartar Life Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.